Changes in Coronary Plaque Composition By Semaglutide Use in Diabetic Patients With Acute Coronary Syndrome: A Randomized Optical Coherence Tomography Trial - ARMYDA - 10 study

Condition studied

non-ST-elevation myocardial infarction (NSTEMI); unstable angina, diabetes mellitus

Investigational medicinal product(s)

Eligibility

Primary endpoint

the change of the maximum macrophage arc (degrees) in non-culprit coronary stenoses from baseline to 24 weeks, measured by OCT, in the semaglutide vs control arm

Endpoint detail

changes from baseline to 24 weeks in OCT parameters (lumen area, plaque volume, fibrous cap thickness, lipid/calcium arcs and lengths), plaque composition (fibrous, fibro-calcific, fibro-atheroma, TCFA), prevalence of healed and macrophage-rich plaques, HbA1c, BMI, and incidence of cardiovascular events and adverse effects.